# Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis

Victoria V. Grunwald,<sup>1</sup> Marcus Hentrich,<sup>2</sup> Xaver Schiel,<sup>3</sup> Annika Dufour,<sup>1</sup> Stephanie Schneider,<sup>1</sup> Michaela Neusser,<sup>1</sup> Marion Subklewe,<sup>1</sup> Michael Fiegl,<sup>1</sup> Wolfgang Hiddemann,<sup>1</sup> Karsten Spiekermann,<sup>1</sup> Maja Rothenberg-Thurley,<sup>1,\*</sup> and Klaus H. Metzeler<sup>1,\*</sup>

<sup>1</sup>Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany; <sup>2</sup>Department of Internal Medicine, Hematology and Oncology, Red Cross Hospital, Munich, Germany; and <sup>3</sup>Department of Oncology, Hematology and Palliative Care, Klinikum Harlaching, Munich, Germany

#### **Key Points**

- We report longitudinal mutational analyses of 2 patients with high-risk MDS and AML experiencing spontaneous disease remissions.
- Both patients had persistent clonal hematopoiesis during remission, harboring all but 1 of the mutations from the initial diagnostic sample.

# Introduction

Spontaneous remission (SR) of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the absence of disease-modifying therapy is rare.<sup>1-5</sup> One review identified 46 cases of AML SRs published between 1950 and 2014.<sup>6</sup> Infections preceded >70% of SRs, leading to the hypothesis that the immunostimulatory effect of severe infections may occasionally induce immune-mediated blast clearance. Others suggested that donor lymphocytes from nonirradiated blood products may induce SR through allo-immune effects.<sup>7-9</sup> However, infections and transfusion-dependent cytopenias are common in AML patients, and thus their association with SRs may be coincidental.<sup>4</sup> SR has also been documented in MDS,<sup>10</sup> particularly in children and young adults with abnormalities of chromosome 7.<sup>11-15</sup>

Over the past 10 years, next-generation sequencing (NGS) techniques led to the identification of novel recurrently mutated genes in myeloid neoplasia (MN), expanding our knowledge about the genetic basis of MN and evolution of premalignant clonal hematopoiesis to MDS or AML. Detailed mutational analyses of patients achieving SR of MN have not yet been reported. Here, we describe the clinical course and sequential genetic analyses of 2 patients with high-risk MDS and AML who achieved SRs.

## **Case description**

### Patient 1

A 59-year-old man with no known history of hematologic disease was evaluated for a suspected rheumatologic disorder. He reported pain in his small joints, night sweats, and generalized exanthema that had started 3 weeks earlier and had improved with low-dose oral steroids and brine bath therapy. Laboratory tests showed neutropenia, mild anemia, and thrombocytopenia (Figure 1; supplemental Table 1). A BM aspirate was hypocellular with dysplastic erythropoiesis and 3% myeloblasts, consistent with a diagnosis of MDS, with a normal karyotype. On histologic examination of a BM trephine biopsy, 30% to 35% CD34<sup>+</sup>/CD117<sup>+</sup> blasts were noted. A repeat BM aspiration (day 18) revealed 18% myeloblasts, and a diagnosis of MDS with excess blasts was made. The patient had stable blood counts, and a search for a donor for an allogeneic stem cell transplantation (ASCT) was initiated. At follow-up visits 5 and 8 weeks later, his blood counts had normalized, and he continued to receive low-dose oral corticosteroids for polyarthritis with proximal interphalangeal joint and ankle pain. At the second visit (day 75), BM aspiration and biopsy showed normal trilineage hematopoiesis without dysplasia or excess blasts. Cytogenetic analysis was not repeated. Seven months after initial presentation, leukopenia and anemia recurred, and a BM aspirate showed 58% myeloblasts. Cytogenetic analysis revealed a tetraploid clone with a 5q deletion. The patient received sequential high-dose cytarabine and mitoxantrone induction chemotherapy,<sup>16</sup> achieved complete remission (CR), and subsequently underwent ASCT from an HLA-matched donor. He is in ongoing CR 21 months after transplantation.

Submitted 6 April 2019; accepted 30 July 2019. DOI 10.1182/ bloodadvances.2019000265. \*M.R.-T. and K.H.M. contributed equally to this study. The full-text version of this article contains a data supplement. © 2019 by The American Society of Hematology

Figure 1. Blood counts and genetic landscape during the disease course of patient 1. BM, bone marrow; NA, not available; SCT, stem cell transplantation; VAF, variant allele frequency.



#### Patient 2

A 72-year-old man was hospitalized for decompensated congestive heart failure. Laboratory testing revealed anemia and thrombocytopenia (Figure 2A; supplemental Table 2). BM aspiration showed marrow infiltration by 85% myeloblasts, and the patient was diagnosed with AML with a normal karyotype and mutated NPM1. Three skin lesions on the abdomen and back were suggestive of extramedullary disease, but skin biopsy was not performed. The patient suffered from multiple comorbidities, including ischemic and valvular heart disease and chronic kidney disease. He decided against initiation of antileukemic therapy and opted for best supportive care. Over the next few weeks, he received 5 units of packed red blood cells. Seven weeks after initial presentation, histologic examination of a skin lesion showed infiltration by myeloid blasts. Soon thereafter, his blood counts improved spontaneously, he became transfusion independent, and his skin lesions disappeared without antileukemic treatment. Eleven weeks after the initial presentation, repeat BM aspiration and biopsy showed no evidence of AML, and quantitative polymerase chain reaction (qPCR) testing for mutated NPM1 was negative. More than 1 year later, the patient was readmitted with weakness and bicytopenia. BM examination confirmed AML recurrence, which tested positive for the NPM1 mutation and now displayed an abnormal karyotype. The patient reaffirmed his decision to forego antileukemic treatment and died a few days later.

## **Methods**

This study was approved by the Institutional Ethics Committee at the University of Munich. Mutation analysis of 68 genes recurrently altered in MN was performed using a previously described NGS assay.<sup>17-19</sup>

## **Results and discussion**

At initial presentation, patient 1 carried 2 distinct RUNX1 mutations and mutations in SRSF2, IDH2, and BCOR (Figure 1; supplemental Table 1). During his SR, BM (day 75) and peripheral blood (day 168) samples tested negative for 1 of the RUNX1 mutations found at initial presentation, but the second RUNX1 mutation and mutations in SRSF2, IDH2, and BCOR were still detected in the BM, albeit at lower allele frequencies. At the time of disease recurrence (day 220), the spectrum of gene mutations in BM was identical to that in the primary presentation, with reappearance of the second RUNX1 mutation. Cytogenetic analysis showed an evolved karyotype with gain of a 5q deletion. After induction chemotherapy (day 299), the patient again reached CR. At that time, 1 RUNX1 mutation and the SRSF2 mutation persisted, whereas the other mutations became undetectable. On day 360 and day 577 (30 and 247 days after ASCT), no mutation was detected consistent with full donor chimerism and ongoing CR.

In patient 2, 8 different gene mutations were identified at the time of primary diagnosis (Figure 2A; supplemental Table 2). During his SR (day 81), the *NPM1* mutation became undetectable in BM by NGS and by qPCR (sensitivity,  $<10^{-5}$ ). All other mutations persisted despite the normalized blood counts and BM morphology. At disease recurrence (day 461), all mutations found initially were detected, including the *NPM1* mutation, and there was clonal evolution on the cytogenetic level.

Neither of our 2 patients presented with fever or severe infection, which have previously been implicated as triggers of immunemediated SR in AML. Patient 1 did not require transfusions before achieving SR, and patient 2 received only irradiated blood products,



Figure 2. Blood counts and genetic landscape during the disease course of patient 2.

which made an allo-immune mechanism unlikely. SR has also been reported in AML patients receiving high-dose corticosteroids.<sup>20</sup> Patient 1 started taking low-dose prednisolone before his initial diagnosis of MDS/AML, but we cannot exclude that direct or immunomodulatory effects of steroids contributed to the SR.<sup>21</sup>

We found that both our patients, on the genetic level, did not reconstitute normal polyclonal hematopoiesis during their clinically defined SR. Instead, both had persistent clonal hematopoiesis that shared most somatic mutations with the malignant clone. In fact, in each patient, only 1 driver mutation found in the AML/MDS specimen became undetectable at the time of SR, while all other mutations persisted. This finding illustrates that premalignant hematopoietic clones can sequentially acquire multiple mutations, yet still sustain normal-appearing hematopoiesis. Gain of a single mutation might then be sufficient to tip the balance and transform clinically asymptomatic clonal hematopoiesis into full-blown MN. The close genetic relationship between the AML/MDS clone and its immediate premalignant ancestor might also explain why, under certain rare circumstances, the premalignant clone can regain a selective advantage over the AML/MDS clone. Although the mechanisms that allowed re-expansion of preleukemic clones in our patients are uncertain, previous case reports suggest that altered cytokine levels or immune function might play a role.

In summary, we report, for the first time, longitudinal mutational profiling of patients with AML or high-risk MDS who achieved SR. Our 2 patients had persistent clonal hematopoiesis during SRs, in

both cases lacking 1 single mutation compared with the malignant clone. This report illustrates the dynamic, and sometimes nonlinear, clonal evolution of MN and provides insights into the genetic mechanisms underlying SR.

## **Acknowledgments**

This work was supported by a clinical research fellowship from the European Hematology Association, and by a grant (DRG SFB 1243, TP A06) from the German Research Council.

## **Authorship**

Contribution: V.V.G., K.S., M.R.-T., and K.H.M coordinated the analyses; M.H., X.S., M.S., M.F., W.H., and K.S. were involved in clinical patient care; V.V.G., M.R.-T. and K.H.M. generated and analyzed sequencing data; A.D., S.S., M.N., M.S., M.F., K.S., and K.H.M. performed other diagnostic testing; V.V.G, M.R.-T., and K.H.M drafted the manuscript; and all coauthors read and approved the final version of the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.N., 0000-0002-2981-3414; K.H.M., 0000-0003-3920-7490.

Correspondence: Klaus H. Metzeler, Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377 Munich, Germany; e-mail: klaus.metzeler@med.lmu.de.

# References

- 1. Maywald O, Buchheidt D, Bergmann J, et al. Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature. Ann Hematol. 2004;83(3):189-194.
- 2. Kremer B, Tsai DE, Debonera F, Cohen PL, Schuster SJ. Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leuk Lymphoma. 2018;59(3):743-745.
- 3. Fozza C, Bellizzi S, Bonfigli S, Campus PM, Dore F, Longinotti M. Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia. *Eur J Haematol.* 2004;73(3):219-222.
- 4. Daccache A, Kizhakekuttu T, Siebert J, Veeder M. Hematologic and cytogenetic spontaneous remission in acute monocytic leukemia (FAB M5b) with trisomy 8. J Clin Oncol. 2007;25(3):344-346.
- 5. Camus V, Etancelin P, Jardin F, et al. Spontaneous remission in three cases of AML M5 with NPM1 mutation. Clin Case Rep. 2015;3(11):955-959.
- 6. Rashidi A, Fisher SI. Spontaneous remission of acute myeloid leukemia. Leuk Lymphoma. 2015;56(6):1727-1734.
- 7. Tzankov A, Ludescher C, Duba HC, et al. Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. *Ann Hematol.* 2001;80(7):423-425.
- Spadea A, Latagliata R, Martinelli E, Concetta Petti M. Transient spontaneous remission in a case of adult acute myelogenous leukaemia. Br J Haematol. 1990;76(1):154.
- 9. Vachhani P, Mendler JH, Evans A, et al. Spontaneous remission in an older patient with relapsed *FLT3* ITD mutant AML. *Case Rep Hematol.* 2016;2016: 1259759.
- 10. Petti MC, Latagliata R, Breccia M, et al. Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. *Haematologica*. 2001;86(12):1277-1280.
- 11. Suzuki D, Kobayashi R, Sano H, et al. Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis. *Int J Hematol.* 2013;97(6):782-785.
- Parker TM, Klaassen RJ, Johnston DL. Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genet Cytogenet. 2008;182(2):122-125.
- Scheurlen W, Borkhardt A, Ritterbach J, Huppertz HI. Spontaneous hematological remission in a boy with myelodysplastic syndrome and monosomy 7. Leukemia. 1994;8(8):1435-1438.
- 14. Leung EW, Woodman RC, Roland B, Abdelhaleem M, Freedman MH, Dror Y. Transient myelodysplastic syndrome associated with isochromosome 7q abnormality. *Pediatr Hematol Oncol.* 2003;20(7):539-545.
- Renneboog B, Hansen V, Heimann P, De Mulder A, Jannsen F, Ferster A. Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol. 1996;92(3):696-698.
- Braess J, Amler S, Kreuzer KA, et al; AML-CG. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. *Leukemia*. 2018;32(12):2558-2571.
- 17. Metzeler KH, Herold T, Rothenberg-Thurley M, et al; AMLCG Study Group. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood.* 2016;128(5):686-698.
- Rothenberg-Thurley M, Amler S, Goerlich D, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598-1608.
- 19. Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. *Haematologica*. 2018;103(11):1853-1861.
- Shimohakamada Y, Shinohara K, Fukuda N. Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol. 2001;74(2):173-177.
- 21. Bagby GC Jr., Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med. 1980;92(1):55-58.